BIOMAT Database Logo BIOMAT Database Logo

Capravirine, a nonnucleoside reverse-transcriptase inhibitor in patients infected with HIV-1: a phase 1 study. 2004

Benjamin E Gewurz, and Mark Jacobs, and Jo Ann Proper, and Thomas A Dahl, and Tamio Fujiwara, and Bruce J Dezube
Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA.

Capravirine is a nonnucleoside reverse-transcriptase inhibitor (NNRTI) with a unique resistance profile. Although single mutations allow resistance to established NNRTIs, human immunodeficiency virus (HIV)-1 must undergo multiple mutations to achieve resistance to capravirine. In the present phase 1 study, capravirine was administered orally for up to 28 days to 55 HIV-1-infected individuals with CD4+ T lymphocyte counts of 50-500 cells/microL. The most frequent adverse events were diarrhea (5%) and nausea (4%), with no drug-related rashes observed. The day 15 median (mean) HIV-1 load decreased by 1.34 (1.45) log(10) copies/mL in the patients receiving 25 mg/kg/day. Capravirine demonstrated potent antiviral activity, even in antiretroviral-experienced patients.

UI MeSH Term Description Entries
D007093 Imidazoles Compounds containing 1,3-diazole, a five membered aromatic ring containing two nitrogen atoms separated by one of the carbons. Chemically reduced ones include IMIDAZOLINES and IMIDAZOLIDINES. Distinguish from 1,2-diazole (PYRAZOLES).
D008297 Male Males
D009325 Nausea An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.
D003967 Diarrhea An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight. Diarrheas
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D013457 Sulfur Compounds Inorganic or organic compounds that contain sulfur as an integral part of the molecule. Sulfur Compound,Compound, Sulfur,Compounds, Sulfur
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human

Related Publications

Benjamin E Gewurz, and Mark Jacobs, and Jo Ann Proper, and Thomas A Dahl, and Tamio Fujiwara, and Bruce J Dezube
Factors associated with virological response to etravirine in nonnucleoside reverse transcriptase inhibitor-experienced HIV-1-infected patients.
January 2010, Antimicrobial agents and chemotherapy,
Benjamin E Gewurz, and Mark Jacobs, and Jo Ann Proper, and Thomas A Dahl, and Tamio Fujiwara, and Bruce J Dezube
Conformational changes in HIV-1 reverse transcriptase induced by nonnucleoside reverse transcriptase inhibitor binding.
October 2004, Current HIV research,
Benjamin E Gewurz, and Mark Jacobs, and Jo Ann Proper, and Thomas A Dahl, and Tamio Fujiwara, and Bruce J Dezube
In vitro selection of mutations in human immunodeficiency virus type 1 reverse transcriptase that confer resistance to capravirine, a novel nonnucleoside reverse transcriptase inhibitor.
June 2006, Antiviral research,
Benjamin E Gewurz, and Mark Jacobs, and Jo Ann Proper, and Thomas A Dahl, and Tamio Fujiwara, and Bruce J Dezube
Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor.
December 1990, Science (New York, N.Y.),
Benjamin E Gewurz, and Mark Jacobs, and Jo Ann Proper, and Thomas A Dahl, and Tamio Fujiwara, and Bruce J Dezube
CYP2B6 polymorphism and nonnucleoside reverse transcriptase inhibitor plasma concentrations in Chinese HIV-infected patients.
October 2010, Therapeutic drug monitoring,
Benjamin E Gewurz, and Mark Jacobs, and Jo Ann Proper, and Thomas A Dahl, and Tamio Fujiwara, and Bruce J Dezube
Burden of nonnucleoside reverse transcriptase inhibitor resistance in HIV-1-infected patients: a systematic review and meta-analysis.
August 2014, AIDS research and human retroviruses,
Benjamin E Gewurz, and Mark Jacobs, and Jo Ann Proper, and Thomas A Dahl, and Tamio Fujiwara, and Bruce J Dezube
High nonnucleoside reverse transcriptase inhibitor resistance levels in HIV-1-infected Zambian mother-infant pairs.
October 2020, AIDS (London, England),
Benjamin E Gewurz, and Mark Jacobs, and Jo Ann Proper, and Thomas A Dahl, and Tamio Fujiwara, and Bruce J Dezube
Summaries for patients. Nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1.
October 2014, Annals of internal medicine,
Benjamin E Gewurz, and Mark Jacobs, and Jo Ann Proper, and Thomas A Dahl, and Tamio Fujiwara, and Bruce J Dezube
Three nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1.
March 2015, Annals of internal medicine,
Benjamin E Gewurz, and Mark Jacobs, and Jo Ann Proper, and Thomas A Dahl, and Tamio Fujiwara, and Bruce J Dezube
Three nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1.
March 2015, Annals of internal medicine,
Copied contents to your clipboard!